Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691873 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
A Phase 4 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00691873 is a Phase 4 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT00691873, a Phase 4 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).
Interventions
- DRUG Placebo
- DRUG Xolair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691873
The ClinicalTrials.gov registry entry for NCT00691873 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00691873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00691873 about?
NCT00691873 is a clinical study titled "Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids". In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administ...
What is the current status of trial NCT00691873?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2006-05. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00691873?
The interventions under investigation include: Placebo (DRUG), Xolair (DRUG).
Who is sponsoring clinical trial NCT00691873?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.